News | July 27, 2021
Sun Pharma Advanced Research Company Q1FY22 loss at Rs. 61.37 Cr
The company posted net loss of Rs.56.69 crores for the period ended June 30, 2020.
The company posted net loss of Rs.56.69 crores for the period ended June 30, 2020.
The Prime Minister announced that 21st June onwards, the Government of India will provide free vaccines to all Indian citizens above 18 years of age
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
The company has posted net loss of Rs. 99.54 crores for the period ended March 31, 2020
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
The company will review FDA's response and decide on appropriate next steps soon.
The company posted net loss of Rs. 55.51 crores for the period ended December 31, 2019.
The collaboration underscores a broader industry shift toward hybrid research models that integrate computational biology with advanced experimental systems
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
While many cases are treatable, a subset can become highly aggressive, spreading to distant organs and resisting conventional therapies
Subscribe To Our Newsletter & Stay Updated
